0
Skip to Content
Huygens & Versteegh
Publications
Contact
HTA news
Huygens & Versteegh
Publications
Contact
HTA news
Publications
Contact
HTA news

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Multiple Sclerosis Journal-ETC
Aug 8
Written by Matthijs Versteegh
multiple sclerosis
Matthijs Versteegh
Previous
Previous

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Next
Next

Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale

Huygens & Versteegh B.V.
Chamber of commerce: 85221155
Contact